ELAC2 and prostate carcinoma: We investigated and graded the prostate lobes of the KO‐TRAMP and A537T‐TRAMP compared with the WT‐TRAMP mice to determine whether mutation of Elac2 can potentiate or exacerbate prostate cancer (Fig 3A and B, and Appendix Fig S3A and B).